Safety and clinical activity of durvalumab monotherapy in patients with hepatocellular carcinoma (HCC).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.4071
Abstract: 4071Background: Durvalumab, an anti-PD-L1 mAb, has shown early and durable clinical activity with manageable safety in an ongoing Phase 1/2, multicenter, open-label study in pts with advanced solid... read more here.
Keywords: durvalumab monotherapy; clinical activity; activity durvalumab; activity ... See more keywords
Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.8517
Abstract: 8517Background: Treatment options for ED-SCLC are limited, with standard first-line platinum and etoposide and second-line topotecan having limited clinical activity. Beyond these agents, no approv... read more here.
Keywords: combination tremelimumab; durvalumab combination; clinical activity; activity durvalumab ... See more keywords